Table 2.
Characteristic | Number (%) |
---|---|
Sex |
|
Male |
46 (54.8) |
Female |
38 (45.2) |
Age (years) |
|
≤60 |
41 (48.8) |
>60 |
43 (51.2) |
Range (median) |
23 to 78 (61.5) |
Clinical manifestation |
|
Abdominal discomfort or pain |
36 (42.9) |
Gastrointestinal bleeding |
24 (28.6) |
Obstruction |
6 (7.2) |
Perforation or rupture |
3 (3.6) |
Weight loss |
2 (2.4) |
Asymptomatic |
13 (15.5) |
Primary tumor site |
|
Stomach |
56 (66.7) |
Small intestine |
20 (23.8) |
Colorectum |
5 (6.0) |
Intraperitoneally with unknown origin |
3 (3.6) |
Tumor size (cm) |
|
≤5 |
41 (48.8) |
5.1 to 10 |
34 (40.5) |
>10 |
9 (10.7) |
Range (median) |
1.5 to 20 (5.3) |
Predominant cell type |
|
Spindle |
63 (75.0) |
Epithelioid |
13 (15.5) |
Mixed |
8 (9.5) |
Mitotic index (per 50 high power fields) |
|
0 to 5 |
53 (63.1) |
5.1 to 10 |
21 (25.0) |
>10 |
10 (11.9) |
Cellularity |
|
Paucicellular |
11 (13.1) |
Moderate |
33 (39.3) |
High |
40 (47.6) |
Necrosis |
|
Yes |
34 (40.5) |
No |
50 (59.5) |
Tumor rupture |
|
Yes |
5 (6.0) |
No |
79 (94.0) |
Risk classification |
|
Very low |
5 (6.0) |
Low |
26 (31.0) |
Moderate |
17 (20.2) |
High |
36 (42.9) |
Follow-up |
|
Relapse-free survival |
59 (70.2) |
Recurrent |
16 (19.1) |
Metastasis | 9 (10.7) |